Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Deutsche Bank Aktiengesellschaft Analyst Says

Gilead Sciences (NASDAQ:GILD) had its target price lifted by analysts at Deutsche Bank Aktiengesellschaft from $135.00 to $155.00 in a research note issued on Wednesday,MarketScreener reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective would indicate a potential upside of 1.13% from the company’s previous close.

Other equities research analysts have also issued research reports about the company. Sanford C. Bernstein reiterated an “outperform” rating and issued a $160.00 price target on shares of Gilead Sciences in a research report on Wednesday. Cantor Fitzgerald increased their target price on shares of Gilead Sciences from $135.00 to $155.00 and gave the company an “overweight” rating in a research report on Wednesday. UBS Group raised their price target on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Bank of America set a $162.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday. Finally, Leerink Partners boosted their target price on shares of Gilead Sciences from $114.00 to $146.00 and gave the company an “outperform” rating in a report on Friday, January 30th. Twenty-four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $150.64.

Gilead Sciences Stock Down 1.6%

Shares of GILD opened at $153.27 on Wednesday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. Gilead Sciences has a 52 week low of $93.37 and a 52 week high of $157.29. The stock has a market capitalization of $190.16 billion, a price-to-earnings ratio of 22.72, a PEG ratio of 0.78 and a beta of 0.36. The stock has a fifty day moving average of $129.01 and a 200-day moving average of $121.77.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 51.04%. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter last year, the business earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, sell-side analysts anticipate that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Monday, November 17th. The stock was sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the sale, the insider directly owned 107,193 shares in the company, valued at $13,491,310.98. The trade was a 20.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the transaction, the director owned 8,920 shares in the company, valued at approximately $1,115,713.60. The trade was a 35.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 319,391 shares of company stock worth $44,141,101 over the last 90 days. Company insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Paulson Wealth Management Inc. boosted its holdings in Gilead Sciences by 1.8% in the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock worth $477,000 after buying an additional 67 shares during the period. Essex Financial Services Inc. lifted its position in shares of Gilead Sciences by 0.9% during the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock worth $948,000 after acquiring an additional 71 shares in the last quarter. Alpha Cubed Investments LLC boosted its holdings in shares of Gilead Sciences by 1.1% in the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after acquiring an additional 75 shares during the period. Personal CFO Solutions LLC grew its position in shares of Gilead Sciences by 1.7% in the fourth quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 76 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC raised its stake in shares of Gilead Sciences by 1.7% during the 4th quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock valued at $546,000 after purchasing an additional 76 shares during the period. Institutional investors own 83.67% of the company’s stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 beat on top and bottom lines — Gilead reported Q4 EPS of $1.86 and revenue of ~$7.9B, ahead of consensus, driven by strong HIV and liver-disease drug sales. This is the primary catalyst for the rally as investors reward visible current cash flow. Reuters: Gilead quarterly results beat Wall Street estimates
• Positive Sentiment: Multiple analyst upgrades and higher price targets — Banks including Morgan Stanley, JPMorgan, Wells Fargo, Needham and others raised PTs and/or ratings after the print, providing buy-side momentum and supporting the stock’s upside. MarketScreener: Morgan Stanley raises PT
• Positive Sentiment: Dividend hike — Board approved a 3.8% quarterly dividend increase to $0.82/share, raising yield and reinforcing the income case for investors. Dividends often support valuation in large-cap biotech. BusinessWire: Dividend announcement
• Neutral Sentiment: Investment case notes — Commentary highlighting Yescarta label expansion and margin/earnings leverage adds longer-term upside potential but is incremental versus the near-term beat/guidance story. Yahoo Finance: Yescarta and dividend story
• Neutral Sentiment: Earnings materials & transcripts available — For detail on pipeline comments and management tone, see the earnings call transcript and slide deck (useful for modelling but not an immediate stock mover). Seeking Alpha: Q4 earnings call transcript
• Negative Sentiment: FY‑2026 guidance light — Gilead set FY‑26 EPS of $8.45–$8.85 and revenue guidance slightly below consensus (~$29.6–30.0B vs. ~30.1B consensus), which prompted an initial sell-off after hours and is a near-term risk to valuation. MSN: Outlook short of Wall Street view
• Negative Sentiment: Mixed analyst signals — Some firms raised price targets but a few maintained cautious ratings or PTs that imply downside versus current levels (e.g., RBC’s PT remains below the stock), creating a split analyst narrative that could cap upside until guidance clarity improves. Benzinga: analyst actions

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.